A full 14 years after founding CRO Clinipace, its longstanding CEO and president, Jeff Williams, is planning to step down.
The chief’s role will be handed over to Jason Monteleone, who founded Pivotal Financial Consulting, a consulting firm with a focus on CROs, while Williams moves into an “expanded advisory role” within the board, according to a statement.
“I am extremely proud of what we have built at Clinipace, but the time has come for me to replace myself and it is my pleasure to welcome Jason Monteleone as CEO,” said Williams.
“After seeing him in action as a consultant to Clinipace over the last several months, I am confident he will build successfully on our company’s 14-year history and lead us into its next phase of growth.”
Williams has over the past three years been an acquisitive chief, buying up European CRO Accovion as well as Hong Kong CRO Choice Pharma, Paragon Biomedical, PFC Pharma, Regulus Pharmaceutical and Worldwide Clinical Research.
It now has more than 800 staffers and has completed more than 1,500 clinical trials.
Monteleone added: “I am honored to join Clinipace on the heels of the remarkable accomplishments that Jeff and his organization have achieved. I am confident that the strong foundation he built, and the talented team here, will serve us well as we continue our quest to make Clinipace the leading mid-market CRO.”